Literature DB >> 23848362

Off-target effects of MEK inhibitors.

Eric M Wauson1, Marcy L Guerra, Barbara Barylko, Joseph P Albanesi, Melanie H Cobb.   

Abstract

The mitogen-activated protein kinases (MAPKs) ERK1/2 regulate numerous cellular processes, including gene transcription, proliferation, and differentiation. The only known substrates of the MAP2Ks MEK1/2 are ERK1/2; thus, MEK inhibitors PD98059, U0126, and PD0325901 have been important tools in determining the functions of ERK1/2. By using these inhibitors and genetically manipulating MEK, we found that ERK1/2 activation is neither sufficient nor necessary for regulated secretion of insulin from pancreatic β cells or secretion of epinephrine from chromaffin cells. We show that both PD98059 and U0126 reduce agonist-induced entry of calcium into cells in a manner independent of their ability to inhibit ERK1/2. Caution should be used when interpreting results from experiments using these compounds.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23848362      PMCID: PMC3859837          DOI: 10.1021/bi4007644

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  14 in total

1.  Regulation of pancreatic beta-cell insulin secretion by actin cytoskeleton remodelling: role of gelsolin and cooperation with the MAPK signalling pathway.

Authors:  Alejandra Tomas; Barbara Yermen; Le Min; Jeffrey E Pessin; Philippe A Halban
Journal:  J Cell Sci       Date:  2006-04-25       Impact factor: 5.285

2.  Rapid activation and nuclear translocation of mitogen-activated protein kinases in response to physiological concentration of glucose in the MIN6 pancreatic beta cell line.

Authors:  C Benes; M P Roisin; H Van Tan; C Creuzet; J Miyazaki; R Fagard
Journal:  J Biol Chem       Date:  1998-06-19       Impact factor: 5.157

3.  Activation of mitogen-activating protein kinase by glucose is not required for insulin secretion.

Authors:  S Khoo; M H Cobb
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-27       Impact factor: 11.205

4.  Extracellularly regulated kinases 1/2 (p44/42 mitogen-activated protein kinases) phosphorylate synapsin I and regulate insulin secretion in the MIN6 beta-cell line and islets of Langerhans.

Authors:  Christine Longuet; Christophe Broca; Safia Costes; El Habib Hani; Dominique Bataille; Stéphane Dalle
Journal:  Endocrinology       Date:  2004-10-21       Impact factor: 4.736

5.  Regulation of calcium influx and catecholamine secretion in chromaffin cells by a cytochrome P450 metabolite of arachidonic acid.

Authors:  E Hildebrandt; J P Albanesi; J R Falck; W B Campbell
Journal:  J Lipid Res       Date:  1995-12       Impact factor: 5.922

6.  The permissive effects of glucose on receptor-operated potentiation of insulin secretion from mouse islets: a role for ERK1/2 activation and cytoskeletal remodelling.

Authors:  J E Bowe; A Chander; B Liu; S J Persaud; P M Jones
Journal:  Diabetologia       Date:  2013-01-24       Impact factor: 10.122

Review 7.  The protein kinases ERK1/2 and their roles in pancreatic beta cells.

Authors:  M Lawrence; C Shao; L Duan; K McGlynn; M H Cobb
Journal:  Acta Physiol (Oxf)       Date:  2008-01       Impact factor: 6.311

8.  C3 toxin activates the stress signaling pathways, JNK and p38, but antagonizes the activation of AP-1 in rat-1 cells.

Authors:  J Beltman; J R Erickson; G A Martin; J F Lyons; S J Cook
Journal:  J Biol Chem       Date:  1999-02-05       Impact factor: 5.157

9.  Identification of a novel inhibitor of mitogen-activated protein kinase kinase.

Authors:  M F Favata; K Y Horiuchi; E J Manos; A J Daulerio; D A Stradley; W S Feeser; D E Van Dyk; W J Pitts; R A Earl; F Hobbs; R A Copeland; R L Magolda; P A Scherle; J M Trzaskos
Journal:  J Biol Chem       Date:  1998-07-17       Impact factor: 5.157

10.  PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo.

Authors:  D R Alessi; A Cuenda; P Cohen; D T Dudley; A R Saltiel
Journal:  J Biol Chem       Date:  1995-11-17       Impact factor: 5.157

View more
  24 in total

1.  KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cells.

Authors:  Dominic Leiser; Michaela Medová; Kei Mikami; Lluís Nisa; Deborah Stroka; Andree Blaukat; Friedhelm Bladt; Daniel M Aebersold; Yitzhak Zimmer
Journal:  Mol Oncol       Date:  2015-04-14       Impact factor: 6.603

2.  Differential Regulation of ERK1/2 and mTORC1 Through T1R1/T1R3 in MIN6 Cells.

Authors:  Eric M Wauson; Marcy L Guerra; Julia Dyachok; Kathleen McGlynn; Jennifer Giles; Elliott M Ross; Melanie H Cobb
Journal:  Mol Endocrinol       Date:  2015-07-13

3.  MEK2 Negatively Regulates Lipopolysaccharide-Mediated IL-1β Production through HIF-1α Expression.

Authors:  Harvinder Talwar; Mohamad Bouhamdan; Christian Bauerfeld; Jaya Talreja; Rifdat Aoidi; Nicolas Houde; Jean Charron; Lobelia Samavati
Journal:  J Immunol       Date:  2019-02-01       Impact factor: 5.422

4.  Regulation of proline-directed kinases and the trans-histone code H3K9me3/H4K20me3 during human myogenesis.

Authors:  Natarajan V Bhanu; Simone Sidoli; Zuo-Fei Yuan; Rosalynn C Molden; Benjamin A Garcia
Journal:  J Biol Chem       Date:  2019-03-14       Impact factor: 5.157

5.  Systemic injection of CK2.3, a novel peptide acting downstream of bone morphogenetic protein receptor BMPRIa, leads to increased trabecular bone mass.

Authors:  Hemanth Akkiraju; Jeremy Bonor; Kristine Olli; Chris Bowen; Beth Bragdon; Harold Coombs; Leah Rae Donahue; Randall Duncan; Anja Nohe
Journal:  J Orthop Res       Date:  2014-10-20       Impact factor: 3.494

6.  Iron deficiency upregulates Egr1 expression.

Authors:  Seung-Min Lee; Sun Bok Lee; Ron Prywes; Christopher D Vulpe
Journal:  Genes Nutr       Date:  2015-05-19       Impact factor: 5.523

7.  ERK1 is dispensable for mouse pancreatic beta cell function but is necessary for glucose-induced full activation of MSK1 and CREB.

Authors:  Michele Leduc; Joy Richard; Safia Costes; Dany Muller; Annie Varrault; Vincent Compan; Julia Mathieu; Jean-François Tanti; Gilles Pagès; Jacques Pouyssegur; Gyslaine Bertrand; Stéphane Dalle; Magalie A Ravier
Journal:  Diabetologia       Date:  2017-07-18       Impact factor: 10.122

8.  Chemoattractant concentration-dependent tuning of ERK signaling dynamics in migrating neutrophils.

Authors:  Elizabeth R Zhang; Shanshan Liu; Lani F Wu; Steven J Altschuler; Melanie H Cobb
Journal:  Sci Signal       Date:  2016-12-13       Impact factor: 8.192

Review 9.  MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms.

Authors:  Pui-Kei Wu; Jong-In Park
Journal:  Semin Oncol       Date:  2015-09-24       Impact factor: 4.929

10.  The effect of MEK1/2 inhibitors on cisplatin-induced acute kidney injury (AKI) and cancer growth in mice.

Authors:  Carolyn N Brown; Daniel J Atwood; Deepak Pokhrel; Kameswaran Ravichandran; Sara J Holditch; Sanskriti Saxena; Makoto Miyazaki; Raphael Nemenoff; Mary C M Weiser-Evans; Danica Galesic Ljubanovic; Melanie S Joy; Charles L Edelstein
Journal:  Cell Signal       Date:  2020-03-16       Impact factor: 4.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.